Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 12427898.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This baseline-vs-treatment study of 20 patients with relapsing-remitting MS investigated whether glatiramer acetate (GA) has a graduated effect on MS inflammatory activity, which was measured using monthly, standard, and triple dose gadolinium (Gd)-enhanced MRI. GA significantly reduced the mean numbers of enhancing lesions/patient/month on both standard dose and triple dose scans, without interactions with the Gd dose. GA is effective in reducing MS activity, independent of the severity of the MRI-detectable inflammatory process.
Medical subject headings
- Immunosuppressive Agents
- Magnetic Resonance Imaging
- Multiple Sclerosis, Relapsing-Remitting
- Peptides